A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
A liposarcoma containing myxomatous tissue. (Dorland, 27th ed)
A multifunctional heterogeneous-nuclear ribonucleoprotein that may play a role in homologous DNA pairing and recombination. The N-terminal portion of protein is a potent transcriptional activator, while the C terminus is required for RNA binding. The name FUS refers to the fact that genetic recombination events result in fusion oncogene proteins (ONCOGENE PROTEINS, FUSION) that contain the N-terminal region of this protein. These fusion proteins have been found in myxoid liposarcoma (LIPOSARCOMA, MYXOID) and acute myeloid leukemia.
Retroperitoneal neoplasms are a diverse group of tumors that originate in the retroperitoneal space, which is the area behind the peritoneum and includes the kidneys, adrenal glands, pancreas, and major blood vessels.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.
A CCAAT-enhancer binding protein that is induced by DNA DAMAGE and growth arrest. It serves as a dominant negative inhibitor of other CCAAT-enhancer binding proteins.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Dioxoles are organic compounds containing a five-membered ring consisting of two oxygen atoms and two carbon atoms, often found as substructures in various natural and synthetic molecules, including certain pharmaceuticals and toxic dioxin pollutants.
A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.
A benign tumor of fibrous or fully developed connective tissue.
Either of a pair of tubular structures formed by DUCTUS DEFERENS; ARTERIES; VEINS; LYMPHATIC VESSELS; and nerves. The spermatic cord extends from the deep inguinal ring through the INGUINAL CANAL to the TESTIS in the SCROTUM.
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
Tumor or cancer of the MALE GENITALIA.
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)
A benign neoplasm derived from connective tissue, consisting chiefly of polyhedral and stellate cells that are loosely embedded in a soft mucoid matrix, thereby resembling primitive mesenchymal tissue. It occurs frequently intramuscularly where it may be mistaken for a sarcoma. It appears also in the jaws and the skin. (From Stedman, 25th ed)
A family of ribonucleoproteins that were originally found as proteins bound to nascent RNA transcripts in the form of ribonucleoprotein particles. Although considered ribonucleoproteins they are primarily classified by their protein component. They are involved in a variety of processes such as packaging of RNA and RNA TRANSPORT within the nucleus. A subset of heterogeneous-nuclear ribonucleoproteins are involved in additional functions such as nucleocytoplasmic transport (ACTIVE TRANSPORT, CELL NUCLEUS) of RNA and mRNA stability in the CYTOPLASM.
The most commonly diagnosed soft tissue sarcoma. It is a neoplasm with a fibrohistiocytic appearance found chiefly in later adult life, with peak incidence in the 7th decade.
A ubiquitous hnRNP protein found in the CELL NUCLEUS and the CYTOPLASM. Translocations that result in the formation of fusion proteins containing parts of RNA-binding protein EWS may play a role in neoplastic processes such as EWING SARCOMA.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
The fold of peritoneum by which the COLON is attached to the posterior ABDOMINAL WALL.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
The portion of the leg in humans and other animals found between the HIP and KNEE.
A reverse developmental process in which terminally differentiated cells with specialized functions revert back to a less differentiated stage within their own CELL LINEAGE.
A sarcoma, usually a liposarcoma or malignant fibrous histiocytoma, with an abundant component of myxoid tissue resembling primitive mesenchyme containing connective tissue mucin. (Stedman, 25th ed)
Tumors or cancer of the MEDIASTINUM.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The farthest or outermost projections of the body, such as the HAND and FOOT.

Induction of a secreted protein by the myxoid liposarcoma oncogene. (1/74)

The TLS-CHOP oncoprotein, found in the majority of human myxoid liposarcomas, consists of a fusion between the transcription factor CHOP/GADD153 and the N terminus of an RNA-binding protein TLS/FUS. Clinical correlation and in vitro transformation assays indicate that the N terminus of TLS plays an important role in oncogenesis by TLS-CHOP. Until now, however, the only activity attributed to the oncoprotein is that of inhibiting the binding of transcription factors of the C/EBP class to certain adipogenic target genes, a function that TLS-CHOP shares with the nononcogenic CHOP protein. Here we report the isolation of a gene, DOL54, that is activated in primary fibroblasts by the expression of TLS-CHOP. DOL54 is expressed in the neoplastic component of human myxoid liposarcomas and increases the tumorigenicity of cells injected in nude mice. Activation of DOL54 requires an intact DNA-binding and dimerization domain in TLS-CHOP, a suitable cellular dimerization partner, and depends on the TLS N terminus. Normal adipocytic differentiation is associated with an early and transient expression of DOL54, and the gene encodes a secreted protein that is tightly associated with the cell surface or extracellular matrix. TLS-CHOP thus leads to the unscheduled expression of a gene that is normally associated with adipocytic differentiation.  (+info)

p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. (2/74)

PURPOSE: The p27(kip1) protein (p27) is a cyclin-dependent kinase inhibitor that has been shown to be an independent prognostic factor in a variety of human neoplasms. Low expression of p27 tends to occur in more aggressive neoplasms. The role of p27 as an independent prognostic factor in the spectrum of myxoid and round-cell liposarcomas has not been examined. MATERIALS AND METHODS: Forty-seven cases of myxoid and round-cell liposarcomas were examined. Clinicopathologic features and immunohistochemical expression of p27 and Ki-67 antigen were studied in all cases. Survival analysis was performed using the log-rank test and the Cox multivariate regression model. RESULTS: The male:female ratio was 1. 4:1, and the mean age at diagnosis was 45 years. The tumors were located in the lower extremities (94%) and retroperitoneum (6%). The median tumor size was 13.5 cm. The median follow-up was 6.3 years, and the overall 5- and 10-year survival rates were 76% and 67%, respectively. Low expression of p27 was identified in 34 cases (72%) and correlated with decreased metastasis-free (P =.026) and overall survival (P =.008). In a multivariate analysis, only round-cell differentiation and low expression of p27 independently predicted decreased metastasis-free and overall survival. CONCLUSION: p27 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms with few or no round-cell differentiation.  (+info)

Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;6). (3/74)

Myxoid and round-cell liposarcomas share the translocation t(12;16)(q13;p11) creating the TLS-CHOP fusion gene as a common genetic alteration. We previously reported several unique characteristics of genomic sequences around the breakpoints in the TLS and CHOP loci, and among them was the presence of consensus recognition motifs of Translin, a protein that associates with chromosomal translocations of lymphoid neoplasms. We further extended our search for Translin binding motifs in sequences adjacent to breakpoints and investigated whether Translin binds to these sequences in vitro by mobility-shift assay. Computer-assisted search found sequences highly homologous (>70%) with Translin binding motifs adjacent to the breakpoints in 10 out of 11 liposarcomas with the TLS-CHOP fusion genes. All of 13 oligonucleotides corresponding to the putative binding sequences in these cases bind to Hela cell extract and also recombinant Translin protein, although the binding affinity of each motif showed considerable differences. The DNA-protein complex formation was inhibited by non-labeled competitor or anti-Translin antibody, suggesting the specificity of the complex formation. Considering the high incidence and specific binding property, the presence of Translin binding motif may be one of the important determinants for the location of breakpoints in the TLS and CHOP genes in liposarcomas.  (+info)

Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. (4/74)

Myxoid liposarcoma (LS), the most common subtype of LS, is known to be characterized by the specific t(12;16) resulting in a TLS-CHOP fusion in almost all cases. We wished to address the following questions: (i) Is this genetic hallmark also present in other types of LS with predominant myxoid change? (ii) What is the proportion of cases with the variant EWS-CHOP fusion? (iii) What is the optimal approach for Southern blot detection of TLS breakpoints? We identified 59 LS characterized histologically by >90% myxoid component, in which frozen tissue tumor was available for DNA extraction. These 59 LS with myxoid features were divided into 2 groups: 42 LS with classic myxoid/round cell appearance (myxoid LS) and 17 well-differentiated LS (WDLS) with a predominant (>90%) myxoid component. Within the myxoid LS group, 29 tumors were low grade and 13 high grade (>20% round cell component). Among the 17 predominantly myxoid WDLS, there were 15 low grade and 2 focally high grade tumors. In addition, we selected as control group, 20 LS of other histological types with minimal or no myxoid change (17 WDLS and 3 pleomorphic LS) and 13 myxofibrosarcomas. Southern blot analysis was performed in all cases using a CHOP cDNA probe, and in all CHOP rearranged cases using a TLS cDNA probe. Probe/enzyme combinations for Southern blot analysis were CHOP exon 3-4 cDNA probe with BamHI or SacI, TLS exon 3-6 cDNA probe with BclI. All 42 cases of myxoid LS showed a CHOP rearrangement and 38 of them also had a TLS rearrangement. Among the 4 myxoid LS without Southern blot evidence of TLS rearrangement, 1 showed an EWS-CHOP fusion by Southern blotting and reverse transcriptase-polymerase chain reaction and in another case, reverse transcriptase-polymerase chain reaction detected a TLS-CHOP fusion transcript. None of the predominantly myxoid WDLS and none of the tumors included in the control group showed rearranegements with CHOP probe. In addition, 12 predominantly myxoid WDLS, 10 other LS, and 5 myxofibrosarcoma from the control group were also tested for TLS rearrangement; all were negative. The TLS-CHOP fusion is highly sensitive and specific for the entity of classic myxoid/round cell LS. Other types of LS, even with a predominant myxoid component, lack the TLS-CHOP rearrangement, confirming that they represent a genetically distinct group of LS. The prevalence of the EWS-CHOP variant fusion was approximately 2% in this series. The optimal enzyme for TLS genomic breakpoint detection is BclI.  (+info)

Myxoid liposarcoma metastatic to the thoracic epidural space without bone involvement: report of two cases. (5/74)

Myxoid liposarcoma can frequently metastasize to extrapulmonary sites. We present two cases of myxoid liposarcoma metastatic to the epidural space. Both patients complained of back pain, but plain radiography revealed no abnormality. MR imaging clearly demonstrated metastatic tumors in the epidural space, but no involvement of vertebra. When patients with myxoid liposarcoma complain of back pain, metastasis in the epidural space should be considered even in patients without bone involvement.  (+info)

Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. (6/74)

PURPOSE: A specific TLS-CHOP fusion gene resulting from the t(12;16) is present in at least 95% of myxoid liposarcomas (MLS). Three common forms of the TLS-CHOP fusion have been described, differing by the presence or absence of TLS exons 6-8 in the fusion product. Type 5-2 (also known as type II) consists of TLS exons 1-5 fused to CHOP exon 2; type 7-2 (also known as type I) also includes TLS exons 6 and 7 in the fusion, whereas type 8-2 (also known as type III) fuses TLS exons 1-8 to CHOP exon 2. We sought to determine the impact of TLS-CHOP fusion transcript structure on clinical outcome in a group of well-characterized MLS cases. We also analyzed P53 status, because this parameter has been found to have a significant prognostic impact in other sarcomas with chromosomal translocations. METHODS: We analyzed TLS-CHOP fusion transcripts by reverse-transcription PCR using RNA extracted from frozen tissue in 82 MLS confirmed previously to harbor a CHOP rearrangement either by Southern blotting or by cytogenetic detection of the t(12;16). Parameters analyzed included age, location, size, percentage of round cell (RC) component, areas of increased cellularity, necrosis, and surgical margins. In 71 (87%) cases, adequate tumor tissue was available for immunohistochemical analysis of P53 status, using DO7 antibody. The Kaplan-Meier method, log-rank, and Cox regression tests were used for survival analyses. RESULTS: Most MLS were >10 cm (73%), arising in the thigh (70%), and localized at presentation (89%). RC component was <5% in 47 (57%) cases and > or =5% in 35 (43%). The TLS-CHOP fusion transcript was type 5-2 in 55 (67%), type 7-2 in 16 cases (20%), and type 8-2 in 8 (10%). One tumor had a unique variant fusion, between exon 6 TLS and exon 2 CHOP. Two other cases (2%) showed an EWS-CHOP fusion transcript. Overexpression of P53 (defined as > or =10% nuclear staining) was detected in 12 (17%) cases. High histological grade (defined as > or =5% RC; P < 0.01), presence of necrosis (> or =5% of tumor mass; P < 0.05), and overexpression of P53 (P < 0.001) correlated with reduced metastatic disease-free survival in localized tumors. The presence of negative surgical margins (P < 0.01) and extremity location (P = 0.02) were found to be significant in predicting local recurrence in the entire group as well as localized cases by univariate and multivariate analysis. Although there was no significant correlation between TLS-CHOP transcript type and histological grade or disease-specific survival, an association was found between the P53 status and type 5-2 fusion (P < 0.01). CONCLUSION: In contrast to some other translocation-associated sarcomas, the molecular variability of TLS-CHOP fusion transcript structure does not appear to have a significant impact on clinical outcome in MLS. Instead, high histological grade (> or =5% RC), presence of necrosis, and P53 overexpression are predictors of unfavorable outcome in localized MLS.  (+info)

A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. (7/74)

Fusion genes consisting of TLS/FUS and CHOP or EWS and CHOP are characteristic markers for myxoid/round cell liposarcomas (MLS/RCLS). Several different structures of the fusion genes were reported in the case of the TLS/FUS-CHOP form, whereas only one type of structure has so far been found for the EWS-CHOP form, which consisted of exons 1 to 7 of the EWS and exons 2 to 4 of the CHOP gene. Here we describe a novel type of EWS-CHOP fusion gene in two cases of MLS/RCLS, which were found in a consecutive analysis of 21 cases. This fusion gene consisted of exons 1 to 10 of the EWS and exons 2 to 4 of the CHOP gene. The two cases with this fusion gene shared several clinical features, such as a large tumor mass, rapid and invasive growth, and local recurrence within 12 months after surgical resection. Histopathological findings also showed common features characterized by the diffuse proliferation of small spindle cells with a primitive mesenchymal appearance. The association of these clinical and histopathological features suggests a distinct biological property for this rare type of fusion product.  (+info)

Giant metastatic myxoid liposarcoma causing cardiac tamponade: a case report. (8/74)

We report a case of a rapidly progressing isolated giant metastatic myxoid liposarcoma to the heart in a 54-year-old man, who presented with acute symptoms of cardiac tamponade. Surgery remains the best treatment option for this rare condition.  (+info)

Liposarcoma is a type of soft tissue sarcoma, which is a cancer that develops in the soft tissues of the body, such as fat, muscle, nerves, blood vessels, and fibrous tissues. Specifically, liposarcoma arises from fat cells (adipocytes) or their precursors.

There are several subtypes of liposarcoma, which differ in their appearance under the microscope, genetic features, and clinical behavior. These include well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic liposarcomas. The most common sites for liposarcoma are the thigh, retroperitoneum (the area behind the abdominal cavity), and the buttock.

Liposarcomas can grow slowly or rapidly, and they may spread to other parts of the body (metastasize) through the bloodstream or lymphatic system. Treatment typically involves surgical removal of the tumor, often followed by radiation therapy and/or chemotherapy. The prognosis for liposarcoma depends on several factors, including the type and grade of the tumor, its size and location, and whether it has spread to other parts of the body.

Liposarcoma, myxoid type, is a specific subtype of liposarcoma, which is a malignant (cancerous) tumor that develops from fat cells. Myxoid liposarcoma is characterized by the presence of a gel-like substance in the tumor tissue. It usually occurs in deep soft tissues, such as muscles, tendons, and ligaments, and can be found in various parts of the body, but it most commonly affects the thigh.

Myxoid liposarcoma tends to grow slowly and has a better prognosis compared to other subtypes of liposarcoma. However, it can still metastasize (spread) to other parts of the body, such as the lungs, bones, and lymph nodes. Treatment typically involves surgical removal of the tumor, with radiation therapy and/or chemotherapy used in some cases to help reduce the risk of recurrence or spread.

It's important to note that while I strive to provide accurate information, my responses should not be used as a substitute for professional medical advice, diagnosis, or treatment.

FUS (Fused in Sarcoma) is a protein that in humans is encoded by the FUS gene. It is primarily located in the nucleus of the cell, but can also be found in the cytoplasm. FUS belongs to the family of RNA-binding proteins, which means it has the ability to bind to RNA molecules and play a role in post-transcriptional regulation of gene expression.

FUS has several functions, including:

1. Transcriptional regulation: FUS can interact with transcription factors and modulate the transcription of genes.
2. mRNA processing: FUS is involved in various aspects of mRNA processing, such as splicing, transport, localization, and stability.
3. DNA repair: FUS plays a role in DNA damage response and repair mechanisms.
4. Translational regulation: FUS can also regulate translation by interacting with ribosomes and other translational factors.

Mutations in the FUS gene have been associated with several neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). These mutations often lead to an abnormal cytoplasmic accumulation of FUS protein, which can form aggregates and contribute to the pathogenesis of these diseases.

Retroperitoneal neoplasms refer to abnormal growths or tumors that develop in the retroperitoneal space. This is the area located behind the peritoneum, which is the membrane that lines the abdominal cavity and covers the abdominal organs. The retroperitoneal space contains several vital structures such as the kidneys, adrenal glands, pancreas, aorta, and lymphatic vessels.

Retroperitoneal neoplasms can be benign or malignant (cancerous). Malignant retroperitoneal neoplasms are often aggressive and can invade surrounding tissues and organs, leading to various complications. Common types of retroperitoneal neoplasms include lymphomas, sarcomas, and metastatic tumors from other primary sites. Symptoms may vary depending on the size and location of the tumor but can include abdominal or back pain, weight loss, and swelling in the legs. Diagnosis typically involves imaging studies such as CT scans or MRI, followed by a biopsy to determine the type and grade of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Neoplasms in adipose tissue refer to abnormal and excessive growths of cells that form tumors within the fatty connective tissue. These neoplasms can be benign or malignant (cancerous). Benign neoplasms, such as lipomas, are slow-growing and typically do not spread to other parts of the body. Malignant neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to distant sites in the body (metastasis). An example of a malignant neoplasm in adipose tissue is liposarcoma. It's important to note that while some neoplasms may not cause any symptoms, others can cause pain, swelling or other uncomfortable sensations, and therefore should be evaluated by a medical professional for proper diagnosis and treatment.

A lipoma is a common, benign (non-cancerous) soft tissue growth. It is composed of adipose or fatty tissue and typically found just beneath the skin, but they can also occur deeper within the body. Lipomas are usually round, moveable, and painless, although they may cause discomfort if they grow large enough to put pressure on nearby nerves or if they're located in a sensitive area. They generally grow slowly over time. Surgical removal is an option if the lipoma becomes bothersome or grows significantly in size. It's important to note that while lipomas are typically harmless, any new lumps or bumps should be evaluated by a healthcare professional to confirm the diagnosis and rule out other more serious conditions.

Transcription Factor CHOP, also known as DNA Binding Protein C/EBP Homologous Protein or GADD153 (Growth Arrest and DNA Damage-inducible protein 153), is a transcription factor that is involved in the regulation of gene expression in response to various stress stimuli, such as endoplasmic reticulum (ER) stress, hypoxia, and DNA damage.

CHOP is a member of the C/EBP (CCAAT/enhancer-binding protein) family of transcription factors, which bind to specific DNA sequences called cis-acting elements in the promoter regions of target genes. CHOP can form heterodimers with other C/EBP family members and bind to their target DNA sequences, thereby regulating gene expression.

Under normal physiological conditions, CHOP is expressed at low levels. However, under stress conditions, such as ER stress, the expression of CHOP is upregulated through the activation of the unfolded protein response (UPR) signaling pathways. Once activated, CHOP can induce the transcription of genes involved in apoptosis, cell cycle arrest, and oxidative stress response, leading to programmed cell death or survival, depending on the severity and duration of the stress signal.

Therefore, CHOP plays a critical role in maintaining cellular homeostasis by regulating gene expression in response to various stress stimuli, and its dysregulation has been implicated in several pathological conditions, including neurodegenerative diseases, cancer, and metabolic disorders.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

Chondrosarcoma is a type of cancer that develops in the cartilaginous tissue, which is the flexible and smooth connective tissue found in various parts of the body such as the bones, ribs, and nose. It is characterized by the production of malignant cartilage cells that can invade surrounding tissues and spread to other parts of the body (metastasis).

Chondrosarcomas are typically slow-growing tumors but can be aggressive in some cases. They usually occur in adults over the age of 40, and men are more commonly affected than women. The most common sites for chondrosarcoma development include the bones of the pelvis, legs, and arms.

Treatment for chondrosarcoma typically involves surgical removal of the tumor, along with radiation therapy or chemotherapy in some cases. The prognosis for chondrosarcoma depends on several factors, including the size and location of the tumor, the grade of malignancy, and whether it has spread to other parts of the body.

Muscle neoplasms are abnormal growths or tumors that develop in the muscle tissue. They can be benign (non-cancerous) or malignant (cancerous). Benign muscle neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant muscle neoplasms, also known as soft tissue sarcomas, can grow quickly, invade nearby tissues, and metastasize (spread) to distant parts of the body.

Soft tissue sarcomas can arise from any of the muscles in the body, including the skeletal muscles (voluntary muscles that attach to bones and help with movement), smooth muscles (involuntary muscles found in the walls of blood vessels, digestive tract, and other organs), or cardiac muscle (the specialized muscle found in the heart).

There are many different types of soft tissue sarcomas, each with its own set of characteristics and prognosis. Treatment for muscle neoplasms typically involves a combination of surgery, radiation therapy, and chemotherapy, depending on the type, size, location, and stage of the tumor.

Human chromosome pair 12 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosomes come in pairs, with one chromosome inherited from each parent. In humans, there are 23 pairs of chromosomes, for a total of 46 chromosomes in each cell. Chromosome pair 12 is the 12th pair of autosomal chromosomes, meaning they are not sex chromosomes (X or Y).

Chromosome 12 is a medium-sized chromosome and contains an estimated 130 million base pairs of DNA. It contains around 1,200 genes that provide instructions for making proteins and regulating various cellular processes. Some of the genes located on chromosome 12 include those involved in metabolism, development, and response to environmental stimuli.

Abnormalities in chromosome 12 can lead to genetic disorders, such as partial trisomy 12q, which is characterized by an extra copy of the long arm of chromosome 12, and Jacobsen syndrome, which is caused by a deletion of the distal end of the long arm of chromosome 12.

Sarcoma is a type of cancer that develops from certain types of connective tissue (such as muscle, fat, fibrous tissue, blood vessels, or nerves) found throughout the body. It can occur in any part of the body, but it most commonly occurs in the arms, legs, chest, and abdomen.

Sarcomas are classified into two main groups: bone sarcomas and soft tissue sarcomas. Bone sarcomas develop in the bones, while soft tissue sarcomas develop in the soft tissues of the body, such as muscles, tendons, ligaments, fat, blood vessels, and nerves.

Sarcomas can be further classified into many subtypes based on their specific characteristics, such as the type of tissue they originate from, their genetic makeup, and their appearance under a microscope. The different subtypes of sarcoma have varying symptoms, prognoses, and treatment options.

Overall, sarcomas are relatively rare cancers, accounting for less than 1% of all cancer diagnoses in the United States each year. However, they can be aggressive and may require intensive treatment, such as surgery, radiation therapy, and chemotherapy.

I apologize for any confusion, but "dioxoles" is not a medical term or concept. It is a chemical term that refers to a specific type of organic compound containing a dioxole ring, which is a six-membered ring consisting of two oxygen atoms and two carbon atoms. Dioxoles can be found in various natural and synthetic substances, but they are not typically relevant to medical definitions or concepts.

If you have any questions related to medical terminology or concepts, I would be happy to help answer them for you.

Tetrahydroisoquinolines (TIQs) are not a medical condition, but rather a class of organic compounds that have been studied in the field of medicine and neuroscience. TIQs are naturally occurring substances found in various foods, beverages, and plants, as well as produced endogenously in the human body. They have been shown to have various pharmacological activities, including acting as weak psychoactive agents, antioxidants, and inhibitors of certain enzymes. Some TIQs have also been implicated in the pathophysiology of certain neurological disorders such as Parkinson's disease. However, more research is needed to fully understand their roles and potential therapeutic applications.

A fibroma is a benign (non-cancerous) tumor that consists primarily of fibrous or connective tissue. It can occur in various parts of the body, including the skin, mouth, and internal organs. The term "fibroma" is often used to describe any benign fibrous growth, but there are specific types of fibromas such as dermatofibroma (found in the skin), oral fibroma (found in the mouth), and benign fibrous histiocytoma (found in soft tissues).

It's important to note that while fibromas are generally harmless, they can cause discomfort or problems depending on their size and location. If a fibroma is causing issues or there's concern about its growth or malignancy, it should be evaluated by a healthcare professional for potential removal or further assessment.

The spermatic cord is a fibrous structure that contains the vas deferens, blood vessels, nerves, and lymphatics, which provide passage for these structures between the abdomen and the scrotum in males. It is covered by several layers of protective sheaths, including the internal spermatic fascia, cremasteric fascia, and external spermatic fascia. The spermatic cord allows the testicles to be located outside the body, which helps maintain a cooler temperature for optimal sperm production.

Leiomyosarcoma is a type of cancer that arises from the smooth muscle cells, which are responsible for the involuntary contractions of various organs and blood vessels. It most commonly occurs in the uterus, soft tissues (such as muscles and fat), and the gastrointestinal tract.

Leiomyosarcomas can vary in their aggressiveness and may spread to other parts of the body (metastasize) through the bloodstream or lymphatic system. The prognosis for leiomyosarcoma depends on several factors, including the location and size of the tumor, the patient's age and overall health, and the extent of metastasis. Treatment typically involves surgical removal of the tumor, along with radiation therapy and/or chemotherapy to help prevent recurrence or spread of the cancer.

An oncogene protein fusion is a result of a genetic alteration in which parts of two different genes combine to create a hybrid gene that can contribute to the development of cancer. This fusion can lead to the production of an abnormal protein that promotes uncontrolled cell growth and division, ultimately resulting in a malignant tumor. Oncogene protein fusions are often caused by chromosomal rearrangements such as translocations, inversions, or deletions and are commonly found in various types of cancer, including leukemia and sarcoma. These genetic alterations can serve as potential targets for cancer diagnosis and therapy.

Genital neoplasms in males refer to abnormal growths or tumors that develop in the male reproductive organs. These can be benign (non-cancerous) or malignant (cancerous).

Malignant genital neoplasms are often referred to as genital cancers. The most common types of male genital cancers include:

1. Penile Cancer: This occurs when cancer cells form in the tissues of the penis.
2. Testicular Cancer: This forms in the testicles (testes), which are located inside the scrotum.
3. Prostate Cancer: This is a common cancer in men, forming in the prostate gland, which is part of the male reproductive system that helps make semen.
4. Scrotal Cancer: This is a rare form of cancer that forms in the skin or tissue of the scrotum.
5. Penile Intraepithelial Neoplasia (PeIN): This is not cancer, but it is considered a pre-cancerous condition of the penis.

Early detection and treatment of genital neoplasms can significantly improve the prognosis. Regular self-examinations and medical check-ups are recommended, especially for individuals with risk factors such as smoking, HIV infection, or a family history of these cancers.

Benign fibrous histiocytoma (BFH) is a common benign tumor of the skin and superficial soft tissues. It primarily affects middle-aged adults and is more prevalent in men than women. The exact cause of BFH is unknown, but it's thought to arise from dermal fibroblasts or histiocytes.

Medical Definition: Benign Fibrous Histiocytoma (BFH) is a benign, slowly growing, solitary cutaneous or subcutaneous nodular tumor predominantly composed of a mixture of fibroblastic and histiocytic-like cells. The tumor typically presents as a well-circumscribed, firm, dome-shaped papule or nodule, ranging in size from a few millimeters to several centimeters. Histologically, BFH is characterized by the proliferation of spindle-shaped fibroblasts and histiocytes arranged in a storiform pattern, along with variable amounts of collagen deposition, multinucleated giant cells, and hemosiderin deposits. The lesion usually has a pushing border with no invasion into the surrounding tissues. BFH generally follows a benign clinical course, with local recurrence being uncommon following complete surgical excision.

A myxoma is a type of benign (non-cancerous) tumor that develops in the heart, specifically in the heart's chambers or valves. It is the most common primary cardiac tumor in adults and typically affects the left atrium. Myxomas are composed of gelatinous, mucoid material and may have a stalk-like attachment to the endocardium (the inner lining of the heart).

Myxomas can vary in size and may cause symptoms such as shortness of breath, fatigue, chest pain, coughing, and fever. These symptoms are due to obstruction of blood flow within the heart or embolization (detachment and travel) of tumor fragments to other parts of the body. Surgical removal is usually required to treat myxomas, as they can lead to serious complications if left untreated.

Heterogeneous Nuclear Ribonucleoproteins (hnRNPs) are a type of nuclear protein complex associated with nascent RNA transcripts in the nucleus of eukaryotic cells. They play crucial roles in various aspects of RNA metabolism, including processing, transport, stability, and translation.

The term "heterogeneous" refers to the diverse range of proteins that make up these complexes, while "nuclear" indicates their location within the nucleus. The hnRNPs are composed of a core protein component and associated RNA molecules, primarily heterogeneous nuclear RNAs (hnRNAs) or pre-messenger RNAs (pre-mRNAs).

There are over 20 different hnRNP proteins identified so far, each with distinct functions and structures. Some of the well-known hnRNPs include hnRNP A1, hnRNP C, and hnRNP U. These proteins contain several domains that facilitate RNA binding, protein-protein interactions, and post-translational modifications.

The primary function of hnRNPs is to regulate gene expression at the post-transcriptional level by interacting with RNA molecules. They participate in splicing, 3' end processing, export, localization, stability, and translation of mRNAs. Dysregulation of hnRNP function has been implicated in various human diseases, including neurological disorders and cancer.

Malignant fibrous histiocytoma (MFH) is not a specific type of histiocytoma; rather, it is a type of soft tissue sarcoma. Histiocytomas are benign tumors that arise from cells called histiocytes, which are part of the immune system. MFH, on the other hand, is a malignant (cancerous) tumor that can arise in various types of soft tissues, such as muscle, fat, tendons, and ligaments.

MFH was once thought to originate from histiocytes, but more recent research suggests that it may actually arise from undifferentiated mesenchymal cells, which are capable of developing into a variety of different cell types. MFH is the most common type of soft tissue sarcoma in adults over the age of 50 and typically presents as a painless mass in the extremities or retroperitoneum (the area in the back of the abdomen).

The tumor is characterized by the presence of fibroblastic and histiocytic-like cells, which can be quite pleomorphic (varied in shape and size) and may contain numerous mitotic figures (indicating rapid cell division). Treatment typically involves surgical excision, often followed by radiation therapy and/or chemotherapy. The prognosis for MFH depends on several factors, including the tumor's location, size, grade (degree of differentiation), and the patient's age and overall health.

Ewing Sarcoma (EWS) RNA-Binding Protein, also known as EWSR1, is a protein that plays a role in gene expression by binding to RNA. It is a member of the FET family of proteins, which also includes FUS and TAF15. These proteins are involved in various cellular processes such as transcription, splicing, and translation.

Mutations in the EWSR1 gene have been associated with several types of cancer, most notably Ewing sarcoma, a rare tumor that typically affects children and adolescents. In Ewing sarcoma, a fusion protein is formed when EWSR1 combines with another protein, most commonly ETS translocation variant 1 (ETV1), FLI1, ERG or FEV. This fusion protein can lead to abnormal gene expression and tumor formation.

EWSR1 has also been found to be involved in other types of cancer such as acute myeloid leukemia, clear cell sarcoma, desmoplastic small round cell tumors and liposarcomas.

It's important to note that while EWSR1 is a RNA-binding protein, it can also bind to DNA in certain contexts, such as when it forms a fusion protein with an ETS transcription factor in Ewing sarcoma.

Human chromosome pair 16 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosomes come in pairs, with one chromosome inherited from each parent. Chromosome pair 16 contains two homologous chromosomes, which are similar in size, shape, and genetic content but may have slight variations due to differences in the DNA sequences inherited from each parent.

Chromosome pair 16 is one of the 22 autosomal pairs, meaning it contains non-sex chromosomes that are present in both males and females. Chromosome 16 is a medium-sized chromosome, and it contains around 2,800 genes that provide instructions for making proteins and regulating various cellular processes.

Abnormalities in chromosome pair 16 can lead to genetic disorders such as chronic myeloid leukemia, some forms of mental retardation, and other developmental abnormalities.

The mesocolon is a peritoneal fold that attaches the colon to the posterior abdominal wall. It contains blood vessels, lymphatics, and nerves that supply the colon. The mesocolon allows for the mobility and flexibility of the colon within the abdominal cavity. There are several parts of the mesocolon, including the mesentery of the ascending colon (right mesocolon), the transverse mesocolon, and the mesentery of the descending and sigmoid colon (left mesocolon).

Translocation, genetic, refers to a type of chromosomal abnormality in which a segment of a chromosome is transferred from one chromosome to another, resulting in an altered genome. This can occur between two non-homologous chromosomes (non-reciprocal translocation) or between two homologous chromosomes (reciprocal translocation). Genetic translocations can lead to various clinical consequences, depending on the genes involved and the location of the translocation. Some translocations may result in no apparent effects, while others can cause developmental abnormalities, cancer, or other genetic disorders. In some cases, translocations can also increase the risk of having offspring with genetic conditions.

Proto-oncogene proteins, such as c-MDM2, are normal cellular proteins that play crucial roles in regulating various cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death). When these genes undergo mutations or are overexpressed, they can become oncogenes, which contribute to the development of cancer.

The c-MDM2 protein is a key regulator of the cell cycle and is involved in the negative regulation of the tumor suppressor protein p53. Under normal conditions, p53 helps prevent the formation of tumors by inducing cell cycle arrest or apoptosis in response to DNA damage or other stress signals. However, when c-MDM2 is overexpressed or mutated, it can bind and inhibit p53, leading to uncontrolled cell growth and increased risk of cancer development.

In summary, proto-oncogene proteins like c-MDM2 are important regulators of normal cellular processes, but when they become dysregulated through mutations or overexpression, they can contribute to the formation of tumors and cancer progression.

In the context of human anatomy, the thigh is the part of the lower limb that extends from the hip to the knee. It is the upper and largest portion of the leg and is primarily composed of the femur bone, which is the longest and strongest bone in the human body, as well as several muscles including the quadriceps femoris (front thigh), hamstrings (back thigh), and adductors (inner thigh). The major blood vessels and nerves that supply the lower limb also pass through the thigh.

Cell dedifferentiation is a process by which a mature, specialized cell reverts back to an earlier stage in its developmental lineage, regaining the ability to divide and differentiate into various cell types. This phenomenon is typically observed in cells that have been damaged or injured, as well as during embryonic development and certain disease states like cancer. In the context of tissue repair and regeneration, dedifferentiation allows for the generation of new cells with the potential to replace lost or damaged tissues. However, uncontrolled dedifferentiation can also contribute to tumor formation and progression.

Myxosarcoma is a very rare type of soft tissue sarcoma, a cancer that develops in the soft tissues of the body, such as fat, muscle, nerves, blood vessels, and fibrous tissues. Myxosarcomas are characterized by the presence of mucoid or gelatinous material in the tumor, which is composed of an abnormal accumulation of acid mucopolysaccharides. These tumors typically affect adults, with a peak incidence in the sixth to seventh decade of life. They usually occur in the extremities, particularly the lower limbs, and can also arise in the retroperitoneum or other deep soft tissues. Myxosarcomas are classified into several subtypes based on their histological features, with the most common being the myxofibrosarcoma. Treatment typically involves surgical resection with wide margins, often followed by radiation therapy and/or chemotherapy. The prognosis for patients with myxosarcoma depends on several factors, including the size and location of the tumor, the histological grade, and the patient's age and overall health.

Mediastinal neoplasms refer to abnormal growths or tumors located in the mediastinum, which is the central compartment of the thoracic cavity that lies between the lungs and contains various vital structures such as the heart, esophagus, trachea, blood vessels, lymph nodes, and nerves. Mediastinal neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can arise from any of the tissues or organs within the mediastinum.

Benign mediastinal neoplasms may include thymomas, lipomas, neurofibromas, or teratomas, among others. These tumors are typically slow-growing and rarely spread to other parts of the body. However, they can still cause symptoms or complications by compressing adjacent structures within the mediastinum, such as the airways, blood vessels, or nerves.

Malignant mediastinal neoplasms are cancerous tumors that can invade and destroy surrounding tissues and may spread (metastasize) to other parts of the body. Common types of malignant mediastinal neoplasms include thymic carcinomas, lymphomas, germ cell tumors, and neuroendocrine tumors. These tumors often require aggressive treatment, such as surgery, radiation therapy, and chemotherapy, to control their growth and spread.

It is important to note that mediastinal neoplasms can present with various symptoms depending on their location, size, and type. Some patients may be asymptomatic, while others may experience cough, chest pain, difficulty breathing, hoarseness, or swallowing difficulties. A thorough diagnostic workup, including imaging studies and biopsies, is necessary to confirm the diagnosis and determine the best course of treatment for mediastinal neoplasms.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

The term "extremities" in a medical context refers to the most distant parts of the body, including the hands and feet (both fingers and toes), as well as the arms and legs. These are the farthest parts from the torso and head. Medical professionals may examine a patient's extremities for various reasons, such as checking circulation, assessing nerve function, or looking for injuries or abnormalities.

A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid liposarcomas are the ... This fusion gene is notated as t(12;22)(q13;12). Micrograph of myxoid liposarcoma. H&E stain MRI of myxoid liposarcoma of high ... Myxoid/round cell liposarcoma". Orpha.net. Retrieved October 27, 2019. Sung; et al. (2000). "Myxoid Liposarcoma: Appearance at ... Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance Efficacy of first-line doxorubicin and ...
MTM1 Myxoid liposarcoma; 613488; DDIT3 Myxoma, intracardiac; 255960; PRKAR1A N syndrome; 310465; POLA N-Acetylglutamate ... extraskeletal myxoid; 612237; TAF15 Chondrosarcoma, extraskeletal myxoid; 612237; TFG Chondrosarcoma, extraskeletal myxoid; ...
... dedifferentiated liposarcoma (DD-LPS); 3) myxoid liposarcoma; 4) pleomorphic liposarcoma; and 5) myxoid pleomorphic liposarcoma ... Myxoid pleomorphic liposarcoma (originally termed pleomorphic myxoid liposarcoma) was first described in a large 2009 study of ... Myxoid pleomorphic liposarcoma (MPL) is an exceptionally rare and highly aggressive form of the liposarcomas that develops in ... The round cell form of myxoid liposarcomas also appears to have a relatively poor prognosis: in various retrospective reviews, ...
... is a cutaneous condition characterized by excess mucin. It resembles myxoid liposarcoma. Benign ... "Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia". Semin Diagn Pathol. 18 (4): 267-73. PMID ...
Crozat A, Aman P, Mandahl N, Ron D (June 1993). "Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma". ... Mutations or fusions of CHOP (e.g. with FUS to form FUS-CHOP) can cause Myxoid liposarcoma. GRCh38: Ensembl release 89: ... November 1992). "Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)". Genes, ... "Fusion of the EWS and CHOP genes in myxoid liposarcoma". Oncogene. 12 (3): 489-94. PMID 8637704. Li G, Scull C, Ozcan L, Tabas ...
"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells". Cancer Research. 70 (6): 2235-44. ...
"Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma". Nature. 363 (6430): 640-4. Bibcode:1993Natur.363.. ... localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3". Cancer Res. 53 (7): 1670-5. PMID 8453640 ... FUS gene rearrangement has been implicated in the pathogenesis of myxoid liposarcoma, low-grade fibromyxoid sarcoma, Ewing ... "Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation". Cancer ...
She suffered from Myxoid liposarcoma, and her left leg was amputated at the hip in 1995. [1] Tracy Ashton Official website ...
"Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases". Histopathology. 62 ( ... Initially considered to be a type of histiocytoma termed fibrous histiocytoma or myxoid variant of malignant fibrous ... been diagnosed as MFS but larger studies indicate that these tumors are far more likely to be dedifferentiated liposarcomas. ...
Myxoid liposarcoma tumors consist of round or slightly fusiform cells in a myxoid matrix, vacuolated lipoblasts (i.e. cells ... and myxoid liposarcoma. Low-grade fibromyxoid sarcomas tend to be less cellular and have less prominent blood vessel than AFST ... Myxoid indicates areas that appear more blue or purple than normal due to their high uptake of the hematoxylin stain.) ... thin-walled blood vessels network in a background of alternating myxoid connective tissue areas and more highly cellular ...
AMSF may be confused with other myxoid-rich soft tissue tumors such as myxoid liposarcoma (MyxLPS), myxofibrosarcoma (MyxoFS), ... Am J Surg Pathol Michal M (1988) Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 194:529 ... Some nodular fasciitis and proliferative fasciitis lesions may have myxoid areas but unlike AMSF tumors are rapidly growing, ... MyxLpS tumors consist of a monotonous cell population arranged in discrete myxoid-cellular clusters with conspicuous thin ...
DNA binding of the oncogenic transcription factor FUS-CHOP and reverses the transcriptional program in myxoid liposarcoma. By ... "Trabectedin Superior to Dacarbazine for Leiomyosarcoma, Liposarcoma". Cancer Network. 21 September 2015. Archived from the ... and that the clinical efficacy data were mainly based on patients with liposarcoma and leiomyosarcoma. However, the pivotal ... for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized. Patients must have ...
... was diagnosed with a Myxoid Liposarcoma in September 2013. Long has pledged to always fundraise for Sarcoma UK alongside her ...
Myxoid liposarcoma: these tumors' neoplastic cells express the FUS-DDIT3 fusion gene in 90% or the EWSR1-DDIT3 fusion gene in ... Extraskeletal myxoid chondrosarcoma: These tumors' neoplastic cells express the EWSR1-NR4A3 fusion gene in most cases or the ... Chen Z, Yang Y, Chen R, Ng CS, Shi H (February 2020). "Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a case report ... Primary pulmonary myxoid sarcoma: Among 27 reported cases of these extremely rare tumors, 17 expressed the EWSR1-CREB1 and 1 ...
1988). "The human int-1 gene is located at chromosome region 12q12-12q13 and is not rearranged in myxoid liposarcoma with t(12; ...
... body Myositis Myotonia atrophica Myotonia mental retardation skeletal anomalies Myotubular myopathy Myxedema Myxoid liposarcoma ...
... liposarcoma MeSH C04.557.450.550.420.425 - liposarcoma, myxoid MeSH C04.557.450.550.710 - myelolipoma MeSH C04.557.450.565 - ... liposarcoma MeSH C04.557.450.795.465.425 - liposarcoma, myxoid MeSH C04.557.450.795.480 - lymphangiosarcoma MeSH C04.557. ...
Myxolipoma Angiomyofibroblastoma Myxoid leiomyosarcoma Myxoid liposarcoma Lipoblastoma Myxofibrosarcoma Myxoid cortical adenoma ... A myxoid tumor is a connective tissue tumor with a "myxoid" background, composed of clear, mucoid substance. This tumoral ... Cutaneous myxoma Intramuscular myxoma Myxoid hamartoma Aggressive angiomyxoma Myxoid leiomyoma Chondromyxoid fibroma Myxoid ... Myxoid matrix in tumor pathology revisited: What's in it for the pathologist?". Virchows Archiv. 456 (2): 181-92. doi:10.1007/ ...
... liposarcoma Sclerosing liposarcoma Inflammatory liposarcoma M8852/0 Fibromyxolipoma Myxolipoma M8852/3 Myxoid liposarcoma ... M8853/3 Round cell liposarcoma M8854/0 Pleomorphic lipoma M8854/3 Pleomorphic liposarcoma M8855/3 Mixed liposarcoma M8856/0 ... Superficial well differentiated liposarcoma Well differentiated liposarcoma of superficial soft tissue M8850/3 Liposarcoma, NOS ... lipoma/angiolipoma M8857/0 Spindle cell lipoma M8857/3 Fibroblastic liposarcoma M8858/3 Dedifferentiated liposarcoma M8860/0 ...
... dedifferentiated liposarcoma, myxoid sarcoma, pleomorphic liposarcoma, and myxoid pleomorphic liposarcoma Atypical lipomatous ... Liposarcoma (includes the following varieties: atypical lipomatous tumor/well-differentiated liposarcoma, ... Many liposarcomas are associated with duplication of part of chromosome 12, which results in extra copies of known cancer- ... Liposarcoma treatment consists of surgical resection, with chemotherapy not being used outside of the investigative setting. ...
... extraskeletal myxoid chondrosarcoma, synovial sarcomas that have a prominent myxoid background, or myxoid liposarcoma. However ... The spindle-shaped cells typically occur in an alternating fibrous and myxoid (i.e. more blue or purple compared to normal ... These findings can differentiate LGFMS from various spindle-shaped cell and myxoid neoplasms including benign soft tissue ... myxoid dermatofibrosarcoma protuberans, or in rare cases, ...
Myxoid lipoblastoma List of cutaneous conditions Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: ... Benign lipoblastomatosis is a tumor consisting of fetal-embryonal adipocytes, frequently confused with a liposarcoma, affecting ...
Myxoid variant: Loose, basophilic matrix, with thick fibrous septa, and foamy histiocytes Lipoma-like variant: Univacuolated ... It is important to separate hiberoma from adult rhabdomyoma, a granular cell tumor and a true liposarcoma. This lesion has been ...
Localized lichen myxedematosus Myxoid cyst (digital mucous cyst, mucous cyst) Myxoid lipoblastoma Neuropathia mucinosa cutanea ... Leiomyosarcoma Lipoma Liposarcoma (atypical lipoma, atypical lipomatous tumor) Lymphangiectasis (lymphangioma) ...
A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid liposarcomas are the ... This fusion gene is notated as t(12;22)(q13;12). Micrograph of myxoid liposarcoma. H&E stain MRI of myxoid liposarcoma of high ... Myxoid/round cell liposarcoma". Orpha.net. Retrieved October 27, 2019. Sung; et al. (2000). "Myxoid Liposarcoma: Appearance at ... Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance Efficacy of first-line doxorubicin and ...
My husband was diagnosed with myxoid liposarcoma on September 10, 2004. ... "low grade mixoid liposarcoma", but when I spoke with the pathologist at Johns Hopkins, he told me that myxoid liposarcoma is ... "low grade mixoid liposarcoma", but when I spoke with the pathologist at Johns Hopkins, he told me that myxoid liposarcoma is ... "low grade mixoid liposarcoma", but when I spoke with the pathologist at Johns Hopkins, he told me that myxoid liposarcoma is ...
... with round cell liposarcomas being highly metastatic, poorly differentiated tumours, whereas myxoid liposarcomas are less ... Overexpression of p53 in myxoid liposarcomas seems to be uncommon, and further studies are needed to confirm this. Liposarcomas ... A myxoid liposarcoma containing , 75% round cell components characterised by solid sheets of primitive round cells with a high ... Myxoid/round cell liposarcoma of the extremities: a clinicopathologic study of 29 cases with particular attention to extent of ...
Myxoid/Round Cell Liposarcoma Cell Therapy. participant.ui.study.eligibility-modal.buttons.check-eligibility ... synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) - Measurable disease according to RECIST v1.1 prior to leukapheresis ... synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) - Measurable disease according to RECIST v1.1 prior to leukapheresis ... myxoid/round cell liposarcoma (MRCLS), melanoma, urothelial, head and neck, ovarian, gastric (stomach), esophagogastric ...
Al Kindi, A. H., Al Kindi, F. A., Al Riyami, M., & Khalil, E. (2023). Giant Mediastinal Myxoid Pleomorphic Liposarcoma. Sultan ... Giant Mediastinal Myxoid Pleomorphic Liposarcoma. https://doi.org/10.18295/squmj.12.2022.064 ...
International prospective registry on local treatment approaches in myxoid liposarcomas. Last updated: February 12, 2020 ... To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS) ...
Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma NCT04197986: Sumanta Pal, M.D., is actively recruiting patients for ...
Myxoid liposarcoma: appearance at MR imaging with histologic correlation. Radiographics. 2000 Jul-Aug. 20(4):1007-19. [QxMD ... 11] On ultrasonography, myxoid liposarcomas appear as complex, hypoechoic masses that do not meet the criteria for a simple ... such as myxoid liposarcoma, that can occur in the popliteal fossa. ... but ultrasound lacks the specificity to differentiate Baker cysts from meniscal cysts or myxoid tumors. Another disadvantage is ...
Subcutaneous myxoid liposarcoma]. Naim A, Benchekroune N, Bouchbika Z, Taoufiq N, Jouhadi H, Sahraoui S, Benider A. Naim A, et ...
6. Myxoid Liposarcoma. Liposarcoma is the second most common soft tissue sarcoma in adults, presenting typically between the ... myxoid/round, and pleomorphic. Myxoid tumours comprise 50% of liposarcomas and have intermediate malignant potential and local ... Often, solid lesions such as myxoid liposarcoma and synovial sarcoma appear as complex cysts on ultrasound and may be mistaken ... Myxoid-Liposarcomas: Inhomogeneous appearance; homogenous with gadolinium. Usually require a biopsy for diagnosis. Conclusion: ...
Most myxoid liposarcomas (MLS) are characterized cytogenetically by a t(12;16)(q13;p11). It is reasonable to assume that this ... Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11) Author ... Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11) ... These tumors included one highly differentiated liposarcoma with abnormal karyotype but no involvement of 12q13, seven lipomas ...
Management of Synovial Sarcoma and Myxoid Liposarcoma. Surg Oncol Clin N Am. 2022 Jul. 31 (3):547-558. [QxMD MEDLINE Link]. ...
myxoid liposarcoma Fri Aug 21, 2009 10:56 am. pattimurphy. 1. adenoid cystic carcinoma Sat Aug 22, 2009 6:13 am. ...
Learn about the different types of liposarcoma and how they are treated. ... Myxoid liposarcoma is the second most common type of liposarcoma. It tends to grow more slowly. Round cell liposarcoma is the ... Where does liposarcoma spread (metastasize)?. Sometimes liposarcoma spreads to other parts of the body. Where liposarcoma ... What are the treatments for liposarcoma?. The main treatment for liposarcoma is surgery to remove the tumor. Liposarcoma can ...
... myxoid cell, pleomorphic and mixed-type cases (7). Low-grade liposarcoma is an expansively growing tumor and so invasion to ... Liposarcoma is one of the most common soft-tissue sarcomas that frequently occurs between the ages of 40 and 70 years (9). ... Huge retroperitoneal liposarcoma with renal involvement requires nephrectomy: A case report and literature review. *Authors: * ... Oh SE, Kim HJ, Choi SJ, Oh SY, Roh CR and Kim JH: A case of huge retroperitoneal liposarcoma in pregnancy. Obstet Gynecol Sci. ...
Myxoid and/or Round-Cell Liposarcoma. The second-most-common family of liposarcomas. Both forms carry the same translocations ( ... Myxoid and/or round-cell liposarcoma appears to be sensitive to eceteinascidin, (Yondelis®), a drug approved in Europe but not ... Pleomorphic Liposarcoma. This is the least common form of liposarcoma, and it also tends to affect an extremity. It is often ... There are three families of liposarcoma: well-differentiated and/or dedifferentiated (~50%), myxoid and/or round cell (~ 40%), ...
Report of the first case of myxoid liposarcoma in Colombia: a rare tumor Luz Fernanda Sua, Nhora María Silva (Author) ...
Malignant degeneration of fat tissue into myxoid liposarcoma has been reported [11]. ...
Effect of Primary Site and Other Prognostic Factors on Survival in Myxoid Liposarcoma. Dickan, A., Gootee, J., Aurit, S., ... Effect of Primary Site and Other Prognostic Factors on Survival in Myxoid Liposarcoma. Dickan, A., Gootee, J., Aurit, S., ... Gootee J, Voth E, Curtin C, Silberstein P, Grant L. Epidemiology and Survivorship of Myxoid Leiomyosarcoma: A National Cancer ... Lee HG, Aurit S, Silberstein P, Gootee J. Primary anatomical site as a prognostic factor for pleomorphic liposarcoma. doi: ...
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res. 2012;2:2. ... leading to responses in myxoid liposarcoma,[49] a tumor with a unique chromosomal rearrangement that also confers increased ...
Myxoid Liposarcoma. • Osteosarcoma. • Prisoners Of War (POW). • Sarcoma. • Spina Biffida. • Suicide Prevention. • Support our ...
Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. ... Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Katarina Engström, Peter Bergh, Pelle Gustafson, Ragnar ...
Myxoid/round cell liposarcomas frequently metastasize, based in part on the percentage of round cells, with rates varying from ... Myxoid and round cell liposarcomas, although histologically different, actually represent two ends of a spectrum for a tumor ... As noted, almost all myxoid/round cell liposarcomas share a common t(12;16)(q13;p11) translocation resulting in the TLS-CHOP ... Histologically, pure myxoid liposarcomas resemble developing fetal adipose tissue, with a multinodular mass of low cellularity ...
... extraskeletal myxoid chondrosarcoma), MDM2 (liposarcoma), DDIT3 (myxoid/ round cell liposarcoma), SS18 (synovial sarcoma), and ... Round cell/high-grade myxoid liposarcoma. Mesenchymal chondrosarcoma. Poorly differentiated synovial sarcoma (small cell ... myxoid liposarcoma, poorly differentiated synovial sarcoma (small cell variant), extraskeletal mesenchymal chondrosarcoma, ... A myxoid matrix associated with some sarcomas is better appreciated in cell-blocks,11-14 which can be highlighted by Alcian ...
An Investigational Platform for the Study of Myxoid Liposarcoma. $250,000 Grant for a Collaborative Study led by:. *Torsten ... miRNA Profiling for Liposarcoma $50,000 Grant for a Study led by Dina Lev, MD. University of Texas M. D. Anderson Cancer Center ... An International Collaborative Study of Liposarcoma - Part II. $250,000 Grant for a Study led by four researchers in three ... Translational Research in Well-Differentiated and Dedifferentiated Liposarcoma. $250,000 Grant for a Study led by:. *Robert ...
miR-135b expression effect on myxoid liposarcoma cell line. GSE73491. DNA microarray analysis of Huh7 and JMJD5KO Huh7 cells.. ...
I was diagnosed with Myxoid Liposarcoma round cell, a very rare soft tissue cancer. This cancer began with a small bump on my ...
Myxoid Liposarcoma: A Single Institute Experience Cho WH, Song WS, Han KH, Jeon DG, Kong CB, Nam HS ... Myxoid liposarcoma arose from the spermatic cord is very rare. Also, it is difficult to diagnose by clinical findings or ... Primary mesenteric liposarcoma is rare. It is difficult to make an accurate preoperative diagnosis of the myxoid type of ... The Magnetic Resonance (MR) Imaging Features of Myxoid Liposarcoma Arising from the Mesentery: a Case Report Ahn T, Lee YH, Lee ...
A phase ll trial evaluated letetresgene autoleucel in the treatment of advanced and metastatic myxoid/round cell liposarcoma. ... synovial sarcoma or myxoid liposarcoma (MLPS) of the extremities or trunk wall. MLPS was the only subtype where EI and ... anti-tumor activity with a tolerable safety profile in patients with advanced and metastatic myxoid/round cell liposarcoma ( ... and recurrent dedifferentiated liposarcoma (DDLPS). Toxicities were manageable and no new safety concerns were identified. ...
  • [ 1 ] The ability to detect Baker cysts is near 100%, but ultrasound lacks the specificity to differentiate Baker cysts from meniscal cysts or myxoid tumors. (medscape.com)
  • These tumors included one highly differentiated liposarcoma with abnormal karyotype but no involvement of 12q13, seven lipomas with various cytogenetic aberrations of 12q13-15, two uterine leiomyomas with t(12;14) (q14-15;q23-24), and one hemangiopericytoma and one chondroma, both of which also had 12q13 changes. (lu.se)
  • Tumors with pure myxoid features are considered to be well differentiated, and to have a good prognosis. (pathologyoutlines.com)
  • LYL-132 is under development for the treatment solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1), synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS), non-small cell lung cancer. (pharmaceutical-technology.com)
  • Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. (wikipedia.org)
  • This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), melanoma, urothelial, head and neck, ovarian, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung (NSCLC), or esophageal cancer that express the MAGE-A4 protein. (participaid.co)
  • Retroperitoneal liposarcoma is a rare malignant tumor with an incidence of 2.5/1,000,000 individuals ( 1 ). (spandidos-publications.com)
  • Some of the tumor was relatively hypocellular with myxoid stroma, low grade nuclear cytology, plexiform small vascular pattern, and readily identified signet ring type lipoblasts (image #3). (pathologyoutlines.com)
  • Myxoid and round cell liposarcomas, although histologically different, actually represent two ends of a spectrum for a tumor which almost always has the same translocation, t(12;16)(q13;p11). (pathologyoutlines.com)
  • The tumor cells are bland, spindled or round, and lie within a myxoid matrix. (pathologyoutlines.com)
  • Spindle-cell liposarcoma is a rare variant of an atypical lipomatous tumor (ie, well-differentiated liposarcoma), and it must be distinguished from a dedifferentiated liposarcoma with metastatic potential and a benign spindle-cell lipoma. (medscape.com)
  • Liposarcoma is a lipogenic tumor of large deep-seated connective tissue spaces. (medscape.com)
  • This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. (mycancergenome.org)
  • The fully enrolled trial is evaluating the safety, immunogenicity and efficacy of CMB305 in combination with atezolizumab, or atezolizumab alone, in a total of 88 patients with locally advanced, relapsed, or metastatic NY-ESO-1 + synovial sarcoma or myxoid/round-cell liposarcoma. (biospace.com)
  • A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. (wikipedia.org)
  • Histologically, pure myxoid liposarcomas resemble developing fetal adipose tissue, with a multinodular mass of low cellularity, particularly centrally. (pathologyoutlines.com)
  • Frequently mutated genes included TP53 (17% of pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas) and PIK3CA (18% of myxoid/round-cell liposarcomas, or MRCs). (kb.se)
  • Myxoid and/or round-cell liposarcomas and pleomorphic liposarcomas have a striking predilection for the limbs, and dedifferentiated liposarcoma occurs predominantly in the retroperitoneum. (medscape.com)
  • Eligibility Details: - Key Inclusion criteria - Age ≥18 and ≤ 75 years - Histologically or cytogenetically confirmed diagnosis of urothelial cancer, melanoma, ovarian cancer, esophageal , esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), head and neck, synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) - Measurable disease according to RECIST v1.1 prior to leukapheresis and lymphodepletionHLA-A*02 positive. (participaid.co)
  • Liposarcoma is a type of cancer known as soft tissue sarcoma . (mskcc.org)
  • I was diagnosed with Myxoid Liposarcoma round cell, a very rare soft tissue cancer. (gofundme.com)
  • Liposarcoma is a malignancy of fat cells (see Liposarcoma in the Pediatric Medicine section and Liposarcoma, Soft Tissue in the Radiology section). (medscape.com)
  • Overall, liposarcomas account for less than 20% of all soft tissue sarcomas, and the average patient age at presentation is 50 years. (medscape.com)
  • With an annual incidence of 2.5 cases per million population, liposarcoma is the most common soft tissue sarcoma, accounting for approximately 17% of all soft tissue sarcomas and 3% of all liposarcomas in the head and neck region (usually the neck and the cheek). (medscape.com)
  • Although liposarcomas account for about 17% of all soft tissue sarcomas, they are involved in only 4% of childhood soft tissue sarcomas. (medscape.com)
  • 6- 9 Diagnosis and, hence, prognostic predictions can be complicated by lesions that often contain admixed components with myxoid and round cell morphologies. (bmj.com)
  • The diagnosis of well-differentiated retroperitoneal liposarcoma with renal involvement was made. (spandidos-publications.com)
  • The diagnosis was well-differentiated retroperitoneal liposarcoma. (spandidos-publications.com)
  • These and other distinct genetic aberrations may aid in the diagnosis of particular liposarcoma subtypes, and they can potentially be targets that can be exploited therapeutically. (medscape.com)
  • Myxoid and round cell liposarcomas are regarded as belonging to a continuous histopathological spectrum characteristic of a chromosome translocation, t(12;16)(q13;p11), resulting in the fusion of the TLS and CHOP genes. (bmj.com)
  • 1- 5 These tumours show a variable clinical behaviour, with round cell liposarcomas being highly metastatic, poorly differentiated tumours, whereas myxoid liposarcomas are less metastatic, moderately and well differentiated tumours, and are associated with a more favourable survival rate. (bmj.com)
  • Round cell liposarcoma is the name given to the more aggressive form of myxoid liposarcoma. (mskcc.org)
  • Thus, apparent myxoid liposarcomas should be sampled thoroughly to ensure that no significant round cell component is present. (pathologyoutlines.com)
  • A spindle-cell variant of well-differentiated liposarcoma is also described. (medscape.com)
  • The concept that round-cell liposarcoma represents the high-grade counterpart of myxoid liposarcoma is generally accepted. (medscape.com)
  • Tumour grade determined by the grading system using the MIB-1 score (MIB-1 system) is a very strong prognostic factor in patients with myxoid liposarcoma. (bmj.com)
  • 10- 12 However, to the best of our knowledge no detailed study of the prognostic significance of tumour grades assigned by a grading system in patients with myxoid liposarcoma has been published. (bmj.com)
  • Lee HG, Aurit S, Silberstein P, Gootee J. Primary anatomical site as a prognostic factor for pleomorphic liposarcoma. (creighton.edu)
  • PURPOSE: This study assessed the treatment outcomes of myxoid liposarcoma in the extremities and investigate the prognostic factors. (koreamed.org)
  • Fusion of this gene and FUS on chromosome 16 or EWSR1 on chromosome 22 induced by translocation generates chimeric proteins in myxoid liposarcomas or Ewing sarcoma. (novusbio.com)
  • We were told two weeks ago, that the results of an extensive biopsy showed no sign of residual liposarcoma. (cancer.org)
  • Well-differentiated liposarcoma tends to occur in deep soft tissues of both the limbs and the retroperitoneum. (medscape.com)
  • The anatomical distribution of liposarcoma appears to be partly related to the histologic type. (medscape.com)
  • Liposarcomas most frequently arise from the deep-seated stroma rather than the submucosal or subcutaneous fat. (medscape.com)
  • These fusion proteins have been found in myxoid liposarcoma (LIPOSARCOMA, MYXOID) and acute myeloid leukemia. (bvsalud.org)
  • The neoplastic cells in these neoplasms contain chromosomal translocations which create one of two fusion genes: the FUS-DDIT3 in ~90% and the EWSR1-DDIT3 fusion gene in up to 10% of myxoid liposarcoma cases. (wikipedia.org)
  • FUS gene mutations have also been found in myxoid liposarcomas, which occur in fatty tissues of the body, and in cancer of the blood-forming cells in the bone marrow called acute myeloid leukemia (AML). (medlineplus.gov)
  • Pleomorphic liposarcoma is extremely rare. (mskcc.org)
  • In conclusion, retroperitoneal liposarcoma is a rare disease with a high rate of recurrence. (spandidos-publications.com)
  • Liposarcoma located in the scrotum is a very rare, and to our knowledge, only a few cases have been described in the radiologic literature. (koreamed.org)
  • Myxoid liposarcoma arose from the spermatic cord is very rare. (koreamed.org)
  • The development of a liposarcoma from a preexisting benign lipoma is rare. (medscape.com)
  • Although any liposarcoma subtype occasionally arises in the subcutis, involvement of the dermis appears to be exceedingly rare. (medscape.com)
  • The clinical and pathological features of 50 patients with myxoid liposarcoma were evaluated, and MIB-1 immunostaining was performed to grade these patients' tumours. (bmj.com)
  • The objective of our study was to determine the relation between clinical outcome and tumour grade defined by a MIB-1 score based grading system in patients with myxoid liposarcoma. (bmj.com)
  • Myxoid liposarcoma is the second most common type of liposarcoma. (mskcc.org)
  • these are classified as combined or mixed-type liposarcomas. (medscape.com)
  • An abnormality of band 12q13 has been associated with the development of liposarcomas. (medscape.com)
  • Liposarcoma normally appears as a slowly enlarging, painless, nonulcerated submucosal mass in a middle-aged person, but some lesions grow rapidly and become ulcerated early. (medscape.com)
  • We reviewed the cases of 50 patients with myxoid liposarcoma who were registered in the pathology files of the National Cancer Centre (NCC), Tokyo, Japan. (bmj.com)
  • These heterozygous mutations drive monoallelic expression and are common in many cancer types, but are especially prevalent in glioblastomas, melanomas, myxoid liposarcomas, liver cancers, and bladder cancers. (uab.edu)
  • The present study reported a case with retroperitoneal liposarcoma managed at Guihang Guiyang Hospital (Guiyang, China), and also performed a literature review on presentation, management and prognosis of this patient. (spandidos-publications.com)
  • H&E stain MRI of myxoid liposarcoma of high grade, in left axillary region of 40 year old man. (wikipedia.org)
  • Preclinical studies, i.e. laboratory studies, suggest that the FUS-DDIT3 fusion gene may act as an oncogene to promote the development of myxoid liposarmas. (wikipedia.org)
  • DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. (bvsalud.org)
  • Well-differentiated liposarcoma has a tendency to regrow after initial treatment. (mskcc.org)